• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [21959 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 6 to 11 years, F508del mutation, RF mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2022     Health Information and Quality Authority (HIQA) HTA of the addition of severe combined immunodeficiency (SCID) to the National Newborn Bloodspot Screening Programme
2022     Agency for Care Effectiveness (ACE) Negative pressure wound therapy for wound management in patients with diabetes (type 1 and 2)
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, 6 to 11 years, F508del mutation, other/unknown mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2022     NIHR Health Technology Assessment programme Telaprevir for the treatment of genotype 1 chronic hepatitis C
2022     NIHR Health Technology Assessment programme Pre-eclampsia in Hospital: Early Induction or Expectant management (PHOENIX)
2022     Agency for Care Effectiveness (ACE) Brentuximab vedotin for treating T-cell lymphoma
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sotorasib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for treating advanced urothelial carcinoma
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcervical radiofrequency ablation with intrauterine ultrasound guidance for uterine fibroids - Addendum to commission H21-14]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: classification of thickened liquids for dysphagia]
2022     Agency for Care Effectiveness (ACE) Ruxolitinib for treating polycythaemia vera
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Implantation via injection under endoscopic ultrasound guidance of 32P-labeled microparticles for unresectable, locally advanced pancreatic tumours - Addendum to commission H21-13]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of HyQvia™ (human normal immunoglobulin 10% and hyaluronidase) – primary and secondary immunodeficiency]
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for treating early or advanced HER2-positive breast cancer
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brivaracetam (epilepsy in children [aged 2 to < 4 years]) - Benefit assessment according to §35a Social Code Book V]
2022     Health Information and Quality Authority (HIQA) Descriptive analysis of COVID-19 epidemiological indicators and associated contextual factors in European countries
2022     Agency for Care Effectiveness (ACE) Poly (ADP-ribose) polymerase inhibitors for treating BRCA-mutated, HER2-negative advanced breast cancer
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vedolizumab (antibiotic refractory chronic pouchitis) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Polatuzumab vedotin for treating relapsed or refractory diffuse large B-cell lymphoma
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lorlatinib (NSCLC) - benefit assessment according to §35a Social Code Book V]
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Pegcetacoplan (paroxysmal nocturnal haemoglobinuria, pretreated patients)]
2022     Agency for Care Effectiveness (ACE) Daratumumab-based regimens for newly diagnosed multiple myeloma
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tepotinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Microwave ablation for liver tumours
2022     Agency for Care Effectiveness (ACE) Acalabrutinib, bortezomib and ibrutinib for treating mantle cell lymphoma
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abrocitinib (atopic dermatitis) - Addendum to Commission A22-06]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Hepatic and portal vein embolization prior to major hepatectomy
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: circulating tumour DNA (liquid biopsy)-based EGFR exon 20 T790M mutation detection in advanced non-small cell lung cancer after previous EGFR-directed therapy]
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for chronic lymphocytic leukaemia
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Stent retriever for the treatment of cerebral artery vasospasm following subarachnoid haemorrhage - Addendum to Commission H21-10]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Post COVID-19 – effective treatment and rehabilitation]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: profile of individuals with a history of cancer infected with SARS-CoV-2 during the first two waves of the pandemic]
2022     Agency for Care Effectiveness (ACE) Osimertinib for treating EGFR mutation-positive non-small-cell lung cancer
2022     Norwegian Institute of Public Health (NIPH) [Operating room ventilation: a health technology assessment]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avapritinib (advanced systemic mastocytosis) - Assessment according to §35a (para. 1., sentence 11)]
2022     Norwegian Institute of Public Health (NIPH) Molecular tests for detection of PIK3CA mutations in men and postmenopausal women with HR+/HER2–, locally advanced or metastatic breast cancer: a health technology assessment
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir (HIV) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anifrolumab (systemic lupus erythematosus) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pegcetacoplan (paroxysmal nocturnal haemoglobinuria, pretreated patients) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     NIHR Health Technology Assessment programme Health-Related Quality of Life in two treatment pathways for newly diagnosed open angle glaucoma and ocular hypertension: an unmasked, multi-centre, randomised controlled trial of initial selective laser trabeculoplasty versus conventional medical therapy
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Vosoritide (achondroplasia, ≥ 2 years)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: immunoglobulin shortage: alternative treatments to nonspecific human immunoglobulins]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Psycho- and sociotherapeutic interventions: Adults - Evidence report on the S3 guideline "Cannabis-related disorders"]
2022     Agency for Care Effectiveness (ACE) Cooral System for the prevention of oral mucositis
2022     Penn Medicine Center for Evidence-based Practice (CEP) Breast cancer risk assessment tools
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Voretigene neparvovec (inherited retinal dystrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Magnetic resonance image guided radiation therapy for patients with cancer
2022     Penn Medicine Center for Evidence-based Practice (CEP) Testosterone reference ranges for gender diverse individuals
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idebenone (Leber hereditary optic neuropathy) - assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2022     Agency for Care Effectiveness (ACE) Robot-assisted endovascular intervention systems for coronary artery disease and other vascular diseases
2022     Penn Medicine Center for Evidence-based Practice (CEP) Structured screening questionnaires for alcohol misuse/alcohol use disorders
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Somatrogon (growth disturbance) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Neuromuscular feedback therapy for paraplegia (Addendum to Commission E21-08)]
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Home-based oral nutritional supplements in cancer patients who require modification of the usual ordinary diet due to mucositis]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: updated recommendations for adjusting antidiabetic medication in type 2 diabetes]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Nicotine replacement therapies to aid smoking cessation
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Home-based oral nutritional supplements in cancer patients with moderate-severe malnutrition undergoing active treatment]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating pharmacological treatment for oropharyngeal mucositis in a patient receiving cancer therapy]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of age limits in the mammography screening programme]
2022     Agency for Care Effectiveness (ACE) Ciclosporin 0.1% eye drops for treating severe keratitis in dry eye disease
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: intravenous iron therapy in adults]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcervical radiofrequency ablation with intrauterine ultrasound guidance for uterine fibroids - Second addendum to commission H21-14]
2022     Agency for Care Effectiveness (ACE) Sodium zirconium cyclosilicate for treating hyperkalaemia
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of the relevance of newborn screening for severe combined immunodeficiency SCID]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Casirivimab/imdevimab (post-exposure prophylaxis of COVID-19) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Dolutegravir with lamivudine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection
2022     Penn Medicine Center for Evidence-based Practice (CEP) Clinical utility of inpatient fall risk assessment
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine/lamivudine/tenofovir disoproxil (HIV infection) - Benefit assessment according to §Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Acarbose for treating type 2 diabetes mellitus
2022     NIHR Health Technology Assessment programme HALT-IT trial (Haemorrhage Alleviation with Tranexamic acid Intestinal System), a large randomised placebo controlled trial among patients with acute gastrointestinal haemorrhage of the effects of tranexamic acid on death and transfusion requirement
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of insulin pump systems for type 1 diabetes patients]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine (HIV infection in adolescents) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Ciclosporin 0.1% eye drops for treating severe vernal keratoconjunctivitis
2022     Norwegian Institute of Public Health (NIPH) Tests for the detection of NTRK gene fusions in patients with locally advanced or metastatic solid tumours
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: relevance of the prerequisite of the use of an immunosuppressant drug for the coverage of biologic agents (gastroenterology and dermatology)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brolucizumab (visual impairment due to diabetic macular oedema) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Recombinant blood products for prophylaxis and management of haemophilia A and B
2022     Austrian Institute for Health Technology Assessment (AIHTA) CAR-T cell-therapies in development, update 2022
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) GLP-1 receptor agonist injections for treating type 2 diabetes mellitus
2022     Austrian Institute for Health Technology Assessment (AIHTA) Regulation and financing of prenatal screening and diagnostic examinations for fetal anomalies in selected European countries
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (urothelial carcinoma, adjuvant) - Benefit assessment according to §35a Social Code Book V]
2022     NIHR Health Technology Assessment programme Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework
2022     Austrian Institute for Health Technology Assessment (AIHTA) [Telemonitoring in Austrian diabetes care: a systematic analysis of evaluation methodologies]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (oesophageal squamous cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Quality improvement strategies in trauma care: review and proposal of 31 novel quality indicators
2022     NIHR Health Services and Delivery Research programme Components of interventions to reduce restrictive practices with children and young people in institutional settings: the Contrast systematic mapping review
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (oesophageal cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Achieving safe surgery after COVID-19 vaccination
2022     NIHR Health Services and Delivery Research programme Assessment and management pathways of older adults with mild cognitive impairment: descriptive review and critical interpretive synthesis
2022     Health Information and Quality Authority (HIQA) Health technology assessment of metabolic surgery for the treatment of comorbid type 2 diabetes and obesity
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tebentafusp (uveal melanoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Impact of COVID-19, gender, race, specialty and seniority on mental health during surgical training: an international study
2022     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Respiratory rehabilitation following hospitalization related to a diagnosis of COVID-19 - an update]
2022     Institute for Clinical and Economic Review (ICER) Betibeglogene autotemcel for beta thalassemia: effectiveness and value
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceftazidime/avibactam (bacterial infection) - Assessment according to §35a (para. 1c) Social Code Book V]
2022     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Mesh versus non-mesh repair of groin hernias: a rapid review